NovoLog (insulin aspart) dosing, indications, interactions, adverse effects, and more (2023)

  • acarbose

    acarbose, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • albiglutide

    albiglutide, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • alogliptin

    alogliptin, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • aripiprazole

    aripiprazole, insulin aspart. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

  • asenapine

    asenapine, insulin aspart. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

  • aspirin

    aspirin increases effects of insulin aspart by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required.

  • atazanavir

    atazanavir decreases effects of insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .

  • azilsartan

    azilsartan increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring.

  • benazepril

    benazepril increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypoglycemic effects. Monitor blood glucose.

  • bitter melon

    bitter melon increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypoglycemia.

  • canagliflozin

    insulin aspart, canagliflozin.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with canagliflozin.canagliflozin, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • candesartan

    candesartan increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring.

  • captopril

    captopril increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood glucose. Monitor blood glucose.

  • chlorpropamide

    chlorpropamide, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • cinnamon

    cinnamon increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor. Potential for hypoglycemia.

  • ciprofibrate

    ciprofibrate increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.

  • ciprofloxacin

    ciprofloxacin increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor. Hyper and hypoglycemia have been reported in patients treated concomitantly with quinolones and antidiabetic agents. Careful monitoring of blood glucose is recommended.

  • clozapine

    clozapine, insulin aspart. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

  • dapagliflozin

    insulin aspart, dapagliflozin.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with dapagliflozin.dapagliflozin, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • darunavir

    darunavir decreases effects of insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .

  • deflazacort

    insulin aspart and deflazacort both decrease serum potassium. Use Caution/Monitor.

  • dexfenfluramine

    dexfenfluramine increases effects of insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Dexfenfluramine enhances glucose uptake in peripheral tissue, increasing risk of hypoglycemia.

  • dichlorphenamide

    dichlorphenamide and insulin aspart both decrease serum potassium. Use Caution/Monitor.

  • disopyramide

    disopyramide increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and disopyramide may require insulin dosage adjustment and increased glucose monitoring.

  • dulaglutide

    dulaglutide, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • empagliflozin

    empagliflozin, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with SGLT2 inhibitors.

  • enalapril

    enalapril increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor.

  • eprosartan

    eprosartan increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring.

  • ertugliflozin

    ertugliflozin, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with ertugliflozin.

  • ethinylestradiol

    ethinylestradiol decreases effects of insulin aspart by pharmacodynamic antagonism. Use Caution/Monitor. Oral contraceptives may decrease hypoglycemic effects of antidiabetics by impairing glucose tolerance. Monitor for glycemic control in diabetic patients.

  • exenatide injectable solution

    exenatide injectable solution, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • exenatide injectable suspension

    exenatide injectable suspension, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • fenfluramine

    fenfluramine increases effects of insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Fenfluramine enhances glucose uptake in peripheral tissue, increasing risk of hypoglycemia.

  • fenofibrate

    fenofibrate increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.

  • fenofibrate micronized

    fenofibrate micronized increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.

  • fenofibric acid

    fenofibric acid increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.

  • fleroxacin

    fleroxacin increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.

  • fluoxetine

    fluoxetine increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and fluoxetine may require insulin dosage adjustment and increased glucose monitoring.

  • fosamprenavir

    fosamprenavir decreases effects of insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .

  • fosinopril

    fosinopril increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor.

  • gemfibrozil

    gemfibrozil increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.

    (Video) Fiasp® FlexTouch® (insulin aspart injection) 100 U/mL: How to Use

  • gemifloxacin

    gemifloxacin increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.

  • glimepiride

    glimepiride, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • glipizide

    glipizide, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • glucagon

    glucagon decreases effects of insulin aspart by pharmacodynamic antagonism. Use Caution/Monitor. Endogenous glucagon is a regulatory hormone that increases blood glucose levels; exogenous glucagon is often used to treat hypoglycemia in patients with diabetes mellitus.

  • glucagon intranasal

    glucagon intranasal decreases effects of insulin aspart by pharmacodynamic antagonism. Use Caution/Monitor. Endogenous glucagon is a regulatory hormone that increases blood glucose levels; exogenous glucagon is often used to treat hypoglycemia in patients with diabetes mellitus.

  • glyburide

    glyburide, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • iloperidone

    iloperidone, insulin aspart. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

  • imidapril

    imidapril increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor.

  • indinavir

    indinavir decreases effects of insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .

  • irbesartan

    irbesartan increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring.

  • isocarboxazid

    isocarboxazid increases effects of insulin aspart by unknown mechanism. Use Caution/Monitor.

  • ketotifen, ophthalmic

    ketotifen, ophthalmic, insulin aspart. Other (see comment). Use Caution/Monitor. Comment: Combination may result in thrombocytopenia (rare). Monitor CBC.

  • lanreotide

    lanreotide increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and somatostatin analogs may require insulin dosage adjustment and increased glucose monitoring.

  • levofloxacin

    levofloxacin increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.

  • linagliptin

    linagliptin, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • linezolid

    linezolid increases effects of insulin aspart by unknown mechanism. Use Caution/Monitor.

  • liraglutide

    liraglutide, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • lisinopril

    lisinopril increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor.

  • lithium

    lithium, insulin aspart. unspecified interaction mechanism. Use Caution/Monitor. Lithium salts may cause either hypoglycemia or hyperglycemia. Insulin dosage adjustment and increased glucose monitoring may be required.

  • lonapegsomatropin

    lonapegsomatropin decreases effects of insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Closely monitor blood glucose when treated with antidiabetic agents. Lonapegsomatropin may decrease insulin sensitivity, particularly at higher doses. Patients with diabetes mellitus may require adjustment of their doses of insulin and/or other antihyperglycemic agents.

  • lopinavir

    lopinavir decreases effects of insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .

  • losartan

    losartan increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring.

  • lurasidone

    lurasidone, insulin aspart. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

  • magnesium salicylate

    magnesium salicylate increases effects of insulin aspart by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required.

  • marijuana

    marijuana decreases effects of insulin aspart by pharmacodynamic antagonism. Use Caution/Monitor.

  • mecasermin

    mecasermin increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects.

  • metformin

    metformin, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • methyltestosterone

    methyltestosterone increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor. It is important to monitor all patients with type 2 diabetes on antidiabetic agents receiving androgens for changes in glycemic control. Potential for hypoglycemia.

  • metoclopramide intranasal

    metoclopramide intranasal increases effects of insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Increased GI motility by metoclopramide may increase delivery of food to the intestines and increase blood glucose. Monitor blood glucose and adjust insulin dosage regimen as needed.

  • metreleptin

    insulin aspart, metreleptin.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of metreleptin with insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinide derivatives) may increase risk for hypoglycemia; may require lower dose of insulin or insulin secretagogue.

  • miglitol

    miglitol, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • moexipril

    moexipril increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor.

  • moxifloxacin

    moxifloxacin increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.

  • nadolol

    nadolol, insulin aspart. Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers delay recovery of normoglycemia after insulin induced hypoglycemia; however, they also inhibit insulin secretion, so long term beta blocker Tx may result in reduced glucose tolerance. Insulin induced hypoglycemia may induce hypertension during non selective beta blocker Tx.

  • nateglinide

    nateglinide, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • nelfinavir

    nelfinavir decreases effects of insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .

  • niacin

    niacin decreases effects of insulin aspart by pharmacodynamic antagonism. Use Caution/Monitor. Concomitant use of insulin and niacin may require insulin dosage adjustment and increased glucose monitoring.

  • octreotide

    octreotide increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and somatostatin analogs may require insulin dosage adjustment and increased glucose monitoring.

  • ofloxacin

    ofloxacin increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.

  • olanzapine

    olanzapine, insulin aspart. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

  • olmesartan

    olmesartan increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring.

    (Video) How to Use Your Insulin Pen

  • opuntia ficus indica

    opuntia ficus indica increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor.

  • paliperidone

    paliperidone, insulin aspart. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

  • pasireotide

    pasireotide increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and somatostatin analogs may require insulin dosage adjustment and increased glucose monitoring.

  • pentamidine

    pentamidine, insulin aspart. unspecified interaction mechanism. Use Caution/Monitor. Pentamidine may cause either hypoglycemia or hyperglycemia followed by the opposing effect. Insulin dosage adjustment and increased glucose monitoring may be required.

  • perindopril

    perindopril increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor.

  • phenelzine

    phenelzine increases effects of insulin aspart by unknown mechanism. Use Caution/Monitor.

  • pindolol

    pindolol, insulin aspart. Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers delay recovery of normoglycemia after insulin induced hypoglycemia; however, they also inhibit insulin secretion, so long term beta blocker Tx may result in reduced glucose tolerance. Insulin induced hypoglycemia may induce hypertension during non selective beta blocker Tx.

  • pioglitazone

    insulin aspart increases toxicity of pioglitazone by unknown mechanism. Use Caution/Monitor. Insulin may increase the fluid retention associated with thiazolidinediones (peroxisome proliferator-activated receptor [PPAR]-gamma agonists).pioglitazone, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • procarbazine

    procarbazine increases effects of insulin aspart by unknown mechanism. Use Caution/Monitor.

  • propranolol

    propranolol, insulin aspart. Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers delay recovery of normoglycemia after insulin induced hypoglycemia; however, they also inhibit insulin secretion, so long term beta blocker Tx may result in reduced glucose tolerance. Insulin induced hypoglycemia may induce hypertension during non selective beta blocker Tx.

  • quetiapine

    quetiapine, insulin aspart. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

  • quinapril

    quinapril increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor.

  • ramipril

    ramipril increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor.

  • rasagiline

    rasagiline increases effects of insulin aspart by unknown mechanism. Use Caution/Monitor.

  • risperidone

    risperidone, insulin aspart. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

  • ritonavir

    ritonavir decreases effects of insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .

  • rosiglitazone

    insulin aspart increases toxicity of rosiglitazone by unknown mechanism. Use Caution/Monitor. Insulin may increase the fluid retention associated with thiazolidinediones (peroxisome proliferator-activated receptor [PPAR]-gamma agonists).rosiglitazone, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • sacubitril/valsartan

    sacubitril/valsartan increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring.

  • salsalate

    salsalate increases effects of insulin aspart by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required.

  • saquinavir

    saquinavir decreases effects of insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .

  • saxagliptin

    saxagliptin, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • selegiline

    selegiline increases effects of insulin aspart by unknown mechanism. Use Caution/Monitor.

  • selegiline transdermal

    selegiline transdermal increases effects of insulin aspart by unknown mechanism. Use Caution/Monitor.

  • semaglutide

    semaglutide, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with GLP-1 agonists may increase hypoglycemia risk. Lowering the insulin dose may reduce hypoglycemia risk.

  • shark cartilage

    shark cartilage increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor. Theoretical interaction.

  • sitagliptin

    sitagliptin, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • sodium sulfate/?magnesium sulfate/potassium chloride

    sodium sulfate/?magnesium sulfate/potassium chloride increases toxicity of insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment.

  • sodium sulfate/potassium sulfate/magnesium sulfate

    sodium sulfate/potassium sulfate/magnesium sulfate increases toxicity of insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment.

  • sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol

    insulin aspart and sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol both decrease serum potassium. Modify Therapy/Monitor Closely.

  • somapacitan

    somapacitan decreases effects of insulin aspart by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Growth hormone products may decrease insulin sensitivity, particularly at higher doses. Antidiabetic agents may require dose adjustment after initiating somapacitan. .

  • somatropin

    somatropin decreases effects of insulin aspart by pharmacodynamic antagonism. Use Caution/Monitor.

  • sulfadiazine

    sulfadiazine increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and sulfonamide antibiotics may require insulin dosage adjustment and increased glucose monitoring.

  • sulfamethoxypyridazine

    sulfamethoxypyridazine increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.

  • sulfisoxazole

    sulfisoxazole increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and sulfonamide antibiotics may require insulin dosage adjustment and increased glucose monitoring.

  • telmisartan

    telmisartan increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring.

  • testosterone intranasal

    testosterone intranasal increases effects of insulin aspart by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Androgens may decrease blood glucose and, therefore, may necessitate a decrease in the dose of antidiabetic medication.

  • timolol

    timolol, insulin aspart. Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers delay recovery of normoglycemia after insulin induced hypoglycemia; however, they also inhibit insulin secretion, so long term beta blocker Tx may result in reduced glucose tolerance. Insulin induced hypoglycemia may induce hypertension during non selective beta blocker Tx.

  • tipranavir

    tipranavir decreases effects of insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .

  • tolazamide

    tolazamide, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • tolbutamide

    tolbutamide, insulin aspart.Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

  • trandolapril

    trandolapril increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor.

    (Video) Tresiba® FlexTouch® (insulin degludec) injection 100 U/mL: How to Use

  • tranylcypromine

    tranylcypromine increases effects of insulin aspart by unknown mechanism. Use Caution/Monitor.

  • triamcinolone acetonide injectable suspension

    triamcinolone acetonide injectable suspension decreases effects of insulin aspart by pharmacodynamic antagonism. Use Caution/Monitor. Corticosteroids may diminish hypoglycemic effect of antidiabetic agents. Monitor blood glucose levels carefully.

  • valsartan

    valsartan increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring.

  • xipamide

    xipamide decreases levels of insulin aspart by increasing renal clearance. Use Caution/Monitor.

  • ziprasidone

    ziprasidone, insulin aspart. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

  • agrimony

    agrimony increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • American ginseng

    American ginseng increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • amitriptyline

    amitriptyline increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • amoxapine

    amoxapine increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • anamu

    anamu increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Theoretical interaction.

  • aspirin rectal

    aspirin rectal increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Large dose of salicylate.

  • aspirin/citric acid/sodium bicarbonate

    aspirin/citric acid/sodium bicarbonate increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Large dose of salicylate.

  • balsalazide

    balsalazide increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Large dose of salicylate.

  • bendroflumethiazide

    bendroflumethiazide decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

  • bexarotene

    bexarotene increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • budesonide

    budesonide decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown.

  • chlorothiazide

    chlorothiazide decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

  • chlorthalidone

    chlorthalidone decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

  • choline magnesium trisalicylate

    choline magnesium trisalicylate increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Large dose of salicylate.

  • chromium

    chromium increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • clomipramine

    clomipramine increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • clonidine

    clonidine decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown. Diminished symptoms of hypoglycemia.clonidine, insulin aspart. Other (see comment). Minor/Significance Unknown. Comment: Decreased symptoms of hypoglycemia. Mechanism: decreased hypoglycemia induced catecholamine production.

  • coenzyme Q10

    coenzyme Q10 increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Monitor insulin requirements.

  • cornsilk

    cornsilk increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

  • cortisone

    cortisone decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown.

  • cyclopenthiazide

    cyclopenthiazide decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

  • damiana

    damiana decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown. Theoretical interaction.

  • danazol

    danazol increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • deflazacort

    deflazacort decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown.

  • desipramine

    desipramine increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • devil's claw

    devil's claw increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • dexamethasone

    dexamethasone decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown.

  • diflunisal

    diflunisal increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Large dose of salicylate.

  • doxepin

    doxepin increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • elderberry

    elderberry increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (in vitro research).

  • eucalyptus

    eucalyptus increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Theoretical interaction.

  • fludrocortisone

    fludrocortisone decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown.

  • fluoxymesterone

    fluoxymesterone increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • fo-ti

    fo-ti increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • forskolin

    forskolin increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Colenol, a compound found in Coleus root, may stimulate insulin release.

    (Video) Insulin Regimens - CRASH! Medical Review Series

  • gotu kola

    gotu kola increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).

  • guanfacine

    guanfacine decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown. Diminished symptoms of hypoglycemia.guanfacine, insulin aspart. Other (see comment). Minor/Significance Unknown. Comment: Decreased symptoms of hypoglycemia. Mechanism: decreased hypoglycemia induced catecholamine production.

  • gymnema

    gymnema increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • horse chestnut seed

    horse chestnut seed increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • hydrochlorothiazide

    hydrochlorothiazide decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

  • hydrocortisone

    hydrocortisone decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown.

  • imipramine

    imipramine increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • indapamide

    indapamide decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

  • isoniazid

    isoniazid decreases effects of insulin aspart by unspecified interaction mechanism. Minor/Significance Unknown.

  • juniper

    juniper increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

  • lofepramine

    lofepramine increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • lycopus

    lycopus increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

  • maitake

    maitake increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (animal research).

  • maprotiline

    maprotiline increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • mesalamine

    mesalamine increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Large dose of salicylate.

  • mesterolone

    mesterolone increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • methyclothiazide

    methyclothiazide decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

  • methylprednisolone

    methylprednisolone decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown.

  • metolazone

    metolazone decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

  • nettle

    nettle increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).

  • nortriptyline

    nortriptyline increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • ofloxacin

    ofloxacin, insulin aspart. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential dysglycemia.

  • oxandrolone

    oxandrolone increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • oxymetholone

    oxymetholone increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • panax ginseng

    panax ginseng increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • pegvisomant

    pegvisomant increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • potassium acid phosphate

    potassium acid phosphate increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

  • potassium chloride

    potassium chloride increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

  • potassium citrate

    potassium citrate increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

  • prednisolone

    prednisolone decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown.

  • prednisone

    prednisone decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown.

  • protriptyline

    protriptyline increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • sage

    sage increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • salicylates (non-asa)

    salicylates (non-asa) increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Large dose of salicylate.

  • Siberian ginseng

    Siberian ginseng increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • sulfasalazine

    sulfasalazine increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Large dose of salicylate.

  • testosterone

    testosterone increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • testosterone buccal system

    testosterone buccal system increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • testosterone topical

    testosterone topical increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • tongkat ali

    tongkat ali increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypoglycemia.

  • trazodone

    trazodone increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

    (Video) Instructions For Using Tresiba® FlexTouch® U-200 (insulin degludec injection)

  • trimipramine

    trimipramine increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • vanadium

    vanadium increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

  • willow bark

    willow bark increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown. Large dose of salicylate.

  • FAQs

    What is the indication for insulin aspart? ›

    Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus. Insulin is a natural hormone produced by beta cells of the pancreas. In non-diabetic individuals, a basal level of insulin is supplemented with insulin spikes following meals.

    What drugs interact with NovoLog? ›

    Most frequently checked interactions
    • albuterol.
    • amlodipine.
    • aspirin.
    • atorvastatin.
    • carvedilol.
    • furosemide.
    • gabapentin.
    • Lantus (insulin glargine)

    What are the contraindications of NovoLog? ›

    The following conditions are contraindicated with this drug.
    ...
    Conditions:
    • low blood sugar.
    • low amount of potassium in the blood.
    • liver problems.
    • decreased kidney function.

    What are the side effects of insulin aspart? ›

    Some side effects can be serious. If you experience any of these symptoms, call your doctor immediately or get emergency treatment:
    • rash and/or itching over the whole body.
    • shortness of breath.
    • wheezing.
    • dizziness.
    • blurred vision.
    • fast heartbeat.
    • sweating.
    • weakness.
    15 May 2020

    What is NovoLog insulin used for? ›

    NovoLog® is a rapid-acting insulin that helps lower mealtime blood sugar spikes in adults and children with diabetes. It has been proven to help control high blood sugar in people with diabetes when taken with a long-acting insulin.

    When is insulin aspart given? ›

    Fiasp®—insulin aspart with dose timing flexibility at mealtime; Fiasp® can be administered at the beginning of the meal or within 20 minutes after starting a meal. See Fiasp® Important Safety Information below. View Fiasp® Prescribing Information.

    What drug class is insulin aspart? ›

    Insulin aspart falls into category B. In animal studies, pregnant animals were given insulin aspart, and some babies had problems. It is very important to maintain control of your blood sugar levels during pregnancy.

    What class of drug is NovoLog? ›

    NOVOLOG (insulin aspart injection) is a rapid-acting human insulin analog used to lower blood glucose.

    Do you take NovoLog before or after meals? ›

    NovoLog is a rapid-acting form of insulin that should be injected below the skin 5 to 10 minutes before meals. Have food ready before injection. After injecting the in- sulin, do not skip a meal or delay eating.

    What is the difference between NovoLog and aspart? ›

    Humalog is the brand-name version of insulin lispro, and Novolog is the brand-name version of insulin aspart. These drugs both help manage blood glucose (sugar) in people with type 1 and type 2 diabetes. Humalog and Novolog are both rapid-acting.

    What is the action of NovoLog? ›

    The primary activity of NovoLogis the regulation of glucose metabolism. Insulins, including NovoLog, bind to the insulin receptors on muscle and fat cells and lower blood glucose by facilitating the cellular uptake of glucose and simultaneously inhibiting the output of glucose from the liver.

    Can you overdose on insulin aspart? ›

    The main danger associated with insulin overdose is the resultant hypoglycemia and its effects on the central nervous system; hypokalemia, hypophosphatemia, and hypomagnesemia also can develop with excess insulin administration.

    What type of insulin is insulin aspart? ›

    NovoLog (insulin aspart) is a fast-acting insulin that controls blood sugar around meal times for both type 1 and type 2 diabetes.

    What is the difference between aspart and regular insulin? ›

    Short-acting insulin analogues (aspart, glulisine, and lispro) are thought to be better than regular human insulin due to faster absorption and faster onset of action, mimicking better the physiological prandial insulin peak of people without diabetes [14, 15] and leading to lower postprandial glucose levels [16].

    What drug class is insulin aspart? ›

    Insulin aspart falls into category B. In animal studies, pregnant animals were given insulin aspart, and some babies had problems. It is very important to maintain control of your blood sugar levels during pregnancy.

    What is the difference between insulin lispro and insulin aspart? ›

    What is the difference between insulin lispro and insulin aspart? Insulin lispro and insulin aspart are two generic forms of fast-acting insulin. However, they are chemically different with slightly different onsets of action. Insulin lispro works within 15 minutes while insulin aspart works within five to 10 minutes.

    Videos

    1. [Part 1] How to individualize insulin therapy in type 2 DM - Dr. Rakesh Sahay, Endocrinology
    (10Min CME)
    2. NAPLEX Review: Diabetes Part 2, Injectable Anti=diabetic Agents
    (pharmaffinity)
    3. Insulin Treatment in Patients with Type 2 Diabetes
    (Emory Department of Medicine)
    4. Diabetes
    (Chad Peterson)
    5. PA - Diabetes
    (Chad Peterson)
    6. Tresiba® (insulin degludec injection) 100 U/mL, 200 U/mL Duration of Action With Dr. Brunton
    (Novo Nordisk HCP Video Library)
    Top Articles
    Latest Posts
    Article information

    Author: Saturnina Altenwerth DVM

    Last Updated: 03/22/2023

    Views: 6282

    Rating: 4.3 / 5 (64 voted)

    Reviews: 87% of readers found this page helpful

    Author information

    Name: Saturnina Altenwerth DVM

    Birthday: 1992-08-21

    Address: Apt. 237 662 Haag Mills, East Verenaport, MO 57071-5493

    Phone: +331850833384

    Job: District Real-Estate Architect

    Hobby: Skateboarding, Taxidermy, Air sports, Painting, Knife making, Letterboxing, Inline skating

    Introduction: My name is Saturnina Altenwerth DVM, I am a witty, perfect, combative, beautiful, determined, fancy, determined person who loves writing and wants to share my knowledge and understanding with you.